Navigation Links
Resverlogix Completes Dosing for ASSERT Trial
Date:5/12/2010

pare the dose and time response relationship for ApoA-I as well as to examine key reverse cholesterol markers involved with HDL functionality.

In related clinical news the parallel Phase 2 ASSURE trial for RVX-208, which announced its first site activation on February 25th, will be reassessing its enrollment procedure. Since the ASSERT trial provides us with data much faster than first anticipated, we can also now apply pertinent findings to the ASSURE trial. In order to expedite enrollment, while continuing our primary patient safety concerns, the ASSURE trial is being voluntarily halted on a temporary basis in order to modify enrollment procedures. "While the ASSERT trial set records for enrollment, the much more intricate ASSURE trial will not for the reason that the inclusion criteria is much more detailed and intensive. ASSURE currently requires a patient must have had a heart attack within the past four weeks. The patient is then required to voluntarily submit to having two invasive Intravascular Ultrasound (IVUS) both at the start and finish of the 90 day drug treatment period. We believe that we can enhance the enrollment procedure by modifying the inclusion criteria. One such option would be to include any patients sent to the Catheter Lab, thus greatly increasing the pool of patients that we would be able to draw from for enrolment in this trial. Patients will also now benefit from any added knowledge that we are about to gain from the successful completion of dosing in the ASSERT trial," stated Donald McCaffrey.

In other news today, Donald J. McCaffrey will be providing an updated corporate and clinical overview at 1:00 pm EDT. A slide presentation will be followed by a question and answer session regarding the impact of the early completion of the ASSERT trial and the enh
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
2. Resverlogix is Presenting at IAS HDL Workshop
3. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Resverlogix Share Option Extension
6. Resverlogix Notice of Conference Call & Webcast
7. /C O R R E C T I O N from Source -- Resverlogix Corp./
8. Industry Leaders Select Resverlogixs RVX-208
9. Resverlogixs Lead Drug Featured in Key Scientific Publication
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 30, 2015 Sanofi, ... for the second quarter of 2015. CEO ... and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in ... - Performance drivers - ...
(Date:7/29/2015)... (Q2 2015: +14% CER / 20% of sales) led the regional ... China , as well as solid contributions from Korea, India ... / Middle East / Africa ... Germany , Turkey and the United ... grew 11%, excluding U.S. HPV sales, on demand across all customer classes. The ...
(Date:7/29/2015)... ... July 29, 2015 , ... G-CON Manufacturing, Inc., ... of their 2nd generation cell therapy POD® design. The 2nd generation portfolio not ... represents a new POD® design. , “G-CON first offered our miniPOD CT ...
(Date:7/29/2015)...  Therapath Neuropathology ( www.Therapath.com ), a leader ... and Military Medical centers both domestically and worldwide.  ... Sweat Gland Nerve Fiber Density (SGNFD) for the ... Demonstration of a reduction in ... skin biopsy is a highly sensitive and specific ...
Breaking Biology Technology:QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Neuropathology services for VA and Military health systems 2
... Atrial Fibrillation, EP Mapping and ... Ablation, PCI and Additional Complex Procedures, ST. ... ) announced today that more than 10,000 procedures ... system utilizes,advanced, magnet-guided navigational technology intended to help,electrophysiologists ...
... Alliance On September 10th, 2007 Hard Rock International ... York City. Legendary artist Willie Nelson,and friends will perform ... "save the planet" motto, Hard Rock,s Ambassadors Of Rock ... Biodiesel Alliance. Award-winning,actors Woody Harrelson and Daryl Hannah will ...
... -- China Kangtai,Cactus Biotech, Inc. (OTC Bulletin Board: ... of a variety of cactus-based,consumer products, announced today ... Cactus Health Cigarettes. In order to develop ... Olympiad, and in an effort to take advantage ...
Cached Biology Technology:Stereotaxis' Niobe System Used to Perform More Than 10,000 Procedures Worldwide 2Stereotaxis' Niobe System Used to Perform More Than 10,000 Procedures Worldwide 3MultiVu Video Feed: Hard Rock's 2007 Ambassadors of Rock Tour Is "On the Road Again" With Music Legend Willie Nelson 2China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch 2China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch 3China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch 4
(Date:7/23/2015)... DUBLIN , July 23, 2015 ... the addition of the "Global Outlook of ... their offering. The global biometrics ... both public and commercial applications owing to the ... will witness a transformation that enhances the growth ...
(Date:7/21/2015)... 21, 2015 Passwords have proven futile ... the recent U.S. Office of Personnel Management breach. ... infosec conundrum, but developers and end-users are concerned ... this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today ... for third party integration. A ...
(Date:7/13/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... secure method to make payments.  With this patent, ... with its groundbreaking voice-direct payment patent application, with ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... University of Adelaide researchers have discovered the first evidence ... clock, limiting food intake to specific times of the day. ... Neuroscience , could lead to new information about how the ... when to keep eating. In the University,s Nerve-Gut Research ...
... received a National Endowment for the Humanities Research Fellowship ... researcher Ancel Keys (1904-2004). The biography is tentatively ... the American Diet. Few people have exerted more ... Ancel Keys. Since joining OU in ...
... University of Massachusetts Medical School (UMMS) has received an ... Administration (FDA) for MBL-HCV1, a monoclonal antibody developed to ... a liver transplant. Complications from chronic HCV ... today. For patients with end-stage liver disease or hepatocellular ...
Cached Biology News:Stomach 'clock' tells us how much to eat 2OU professor receives national fellowship to complete biography on Ancel Keys and the American diet 2MassBiologics receives orphan drug status from FDA for hepatitis C treatment 2
...
... depletion cocktail is tailored to ... from suspensions of non-human primate ... separated using the StemSep compatible ... system. The CD4+ T cell ...
... PW is an intelligent full microplate washer with ... simultaneously. This instrument gives you the best of ... efficiency , Performance ,Separate wash ... wash efficiency. A dispense precision of better than ...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
Biology Products: